Compositions comprising chimeric antigen receptors, t cells comprising the same, and methods of using the same
US-2018134802-A1 · May 17, 2018 · US
Tumor specific antibody conjugates and uses therefor
US11554181B2 · US · B2
| Field | Value |
|---|---|
| Publication number | US-11554181-B2 |
| Application number | US-201916559110-A |
| Country | US |
| Kind code | B2 |
| Filing date | Sep 3, 2019 |
| Priority date | Sep 5, 2014 |
| Publication date | Jan 17, 2023 |
| Grant date | Jan 17, 2023 |
How to read this patent
A practical reading order for non-experts. Skip the full description unless you need deep technical detail.
- Title
What the patent document calls the invention.
- Abstract
A short plain-language summary of the technical disclosure.
- Assignees and inventors
Who owns or filed the patent and who is credited as inventor.
- Key dates
Filing, priority, publication, and grant dates set the timeline.
- First independent claim
The legal scope of protection — read this for what is actually claimed.
- CPC / IPC classifications
Technology tags used to group this patent with similar filings.
- Citations and related patents
Prior art links and similar publications in this corpus.
Abstract
Official abstract text for this publication.
Provided are antibodies, and fragments, derivatives, and nanoparticle conjugates thereof, particularly humanized derivatives thereof, which bind to tumor antigens. Also provided are nucleic acid molecules encoding chimeric antigen receptors (CARs) that bind to tumor antigens, polypeptides and CARs encoded by the nucleic acid molecules, vectors and host cells that include the nucleic acid molecules, methods of making the same, and methods for using the same to generate a persisting population of genetically engineered T cells in a subject, expanding a population of genetically engineered T cells in a subject, modulating the amount of cytokine secreted by a T cell, reducing the amount of activation-induced calcium influx into a T cell, providing an anti-tumor immunity to a subject, treating a mammal having a MUC1-associated disease or disorder, stimulating a T cell-mediated immune response to a target cell population or tissue in a subject, and imaging a MUC1-associated tumor.
First claim
Opening claim text (preview).
What is claimed is: 1. An nucleic acid molecule comprising, consisting essentially of, or consisting of any of SEQ ID NOs: 37-42, or that encodes any of SEQ ID NOs: 43-53. 2. The nucleic acid molecule of claim 1 , wherein the nucleic acid molecule comprises SEQ ID NO: 37. 3. The nucleic acid molecule of claim 1 , wherein the nucleic acid molecule comprises SEQ ID NO: 38. 4. The nucleic acid molecule of claim 1 , wherein the nucleic acid molecule comprises SEQ ID NO: 39. 5. The nucleic acid molecule of claim 1 , wherein the nucleic acid molecule comprises SEQ ID NO: 40. 6. The nucleic acid molecule of claim 1 , wherein the nucleic acid molecule comprises SEQ ID NO: 41. 7. The nucleic acid molecule of claim 1 , wherein the nucleic acid molecule comprises SEQ ID NO: 42. 8. The nucleic acid molecule of claim 1 , wherein the nucleic acid molecule encodes SEQ ID NO: 43. 9. The nucleic acid molecule of claim 1 , wherein the nucleic acid molecule encodes SEQ ID NO: 44. 10. The nucleic acid molecule of claim 1 , wherein the nucleic acid molecule encodes SEQ ID NO: 45. 11. The nucleic acid molecule of claim 1 , wherein the nucleic acid molecule encodes SEQ ID NO: 46. 12. The nucleic acid molecule of claim 1 , wherein the nucleic acid molecule encodes SEQ ID NO: 47. 13. The nucleic acid molecule of claim 1 , wherein the nucleic acid molecule encodes SEQ ID NO: 48. 14. The nucleic acid molecule of claim 1 , wherein the nucleic acid molecule encodes SEQ ID NO: 49. 15. The nucleic acid molecule of claim 1 , wherein the nucleic acid molecule encodes SEQ ID NO: 50. 16. The nucleic acid molecule of claim 1 , wherein the nucleic acid molecule encodes SEQ ID NO: 51. 17. The nucleic acid molecule of claim 1 , wherein the nucleic acid molecule encodes SEQ ID NO: 52. 18. The nucleic acid molecule of claim 1 , wherein the nucleic acid molecule encodes SEQ ID NO: 53.
Assignees
Inventors
Classifications
heterozygous knock out animals displaying phenotype · CPC title
Single chain antibody (scFv) · CPC title
Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca · CPC title
maintaining or altering function, i.e. knock in · CPC title
fusions for targeting to specific cell types, e.g. tissue specific targeting, targeting of a bacterial subspecies · CPC title
Patent family
Related publications grouped by family.
External sources
Frequently asked questions
Answers are generated from the same data shown on this page.
- What does patent US11554181B2 cover?
- Provided are antibodies, and fragments, derivatives, and nanoparticle conjugates thereof, particularly humanized derivatives thereof, which bind to tumor antigens. Also provided are nucleic acid molecules encoding chimeric antigen receptors (CARs) that bind to tumor antigens, polypeptides and CARs encoded by the nucleic acid molecules, vectors and host cells that include the nucleic acid molecu…
- Who is the assignee on this patent?
- Univ North Carolina Charlotte, Oncotab Inc
- What technology area does this patent fall under?
- Primary CPC classification A61K47/6851. Mapped technology areas include Human Necessities.
- When was this patent published?
- Publication date Tue Jan 17 2023 00:00:00 GMT+0000 (Coordinated Universal Time) (B2). Legal status and post-grant events are not shown on this page.
- What related patents are in patentsdb?
- We list 6 related publications on this page (citations in our corpus or others sharing the same primary CPC).